X4 Pharmaceuticals

X4 Pharmaceuticals is a biopharmaceutical company headquartered in Boston, Massachusetts, and publicly traded on the Nasdaq Global Market under the symbol XFOR. According to its own materials, X4 develops and commercializes innovative therapies for patients with rare diseases of the immune system and significant unmet needs. The company states that it has successfully developed mavorixafor, receiving U.S. approval for XOLREMDI (mavorixafor) in its first indication, and that it is advancing mavorixafor for additional patient populations while enrolling participants in a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders.

X4 Pharmaceuticals describes itself as delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. The company states that it has successfully developed mavorixafor, receiving U.S. approval for XOLREMDI (mavorixafor) in its first indication, and that it is currently advancing mavorixafor for additional patient populations while enrolling participants in a pivotal, global Phase 3 clinical trial (the 4WARD trial) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts, and is publicly traded on the Nasdaq Global Market under the symbol XFOR.

Developing and commercializing innovative therapies for patients with rare diseases of the immune system and significant unmet needs.

• XOLREMDI (mavorixafor)

• mavorixafor

• 2026.11.04

  Reported2026.11.04

  X4 Pharmaceuticals reports third-quarter 2026 results[3]X4 Pharmaceuticals公布2026年第三季度业绩manilatimes.net

  X4 Pharmaceuticals reported financial results for the third quarter ended September 30, 2026, including revenue of $2.9 million and a net loss of $20.2 million for the three months.

• 2026.11.04

  Reported2026.11.04

  X4 secures term loan facility of up to $150 million[3]X4 Pharmaceuticals公布2026年第三季度业绩manilatimes.net

  X4 Pharmaceuticals said it secured a senior term loan facility of up to $150 million with K2 HealthVentures LLC, replacing a prior loan agreement.

• 2019.09.18

  Reported2019.09.23

  X4 Pharmaceuticals appoints William E. Aliski to its board[4]X4 Pharmaceuticals任命William E. Aliski加入董事会biospace.com

  X4 Pharmaceuticals appointed William E. Aliski to its Board of Directors, effective September 18, 2019.

Read more

1. 1Home - X4 Pharmaceuticalsx4pharma.com
2. 2About - X4 Pharmaceuticalsx4pharma.com
3. 3X4 Pharmaceuticals公布2026年第三季度业绩manilatimes.net
4. 4X4 Pharmaceuticals任命William E. Aliski加入董事会biospace.com
5. 5X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updatefinance.yahoo.com